Microfluidizer Processors for Pharmaceuticals
Microfluidizer processors enable researchers to accomplish the previously impossible, such
as the development of innovative methods for targeted drug delivery using multi-functional
nanomedicine.
More than 1,100 pharmaceutical companies — including 19 of the top 20 — rely on
Microfluidization technology as the undisputed gold standard for uniform particle size
reduction for nanoemulsions, dispersions, nanoencapsulation and cell disruption. Customers
such as Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck,
Novartis, Pfizer, Schering-Plough and Wyeth have all published the use of our dedicated
pharmaceutical homogenizers/processors to develop and produce well-known drugs and vaccines
on the market today.
From startups to contract manufacturers to global pharma, nearly two-thirds of the more than
3,000 Microfluidizer processors installed worldwide are used for biopharmaceutical
applications. By reducing particle size uniformly, we help pharma leaders improve the
quality, bioavailability, stability and process efficiency of their drugs.
Proven Process Efficiency
From startups to contract manufacturers to global pharma, nearly two-thirds of the more than
3,000 Microfluidizer processors installed worldwide are used for biopharmaceutical
applications. By reducing particle size uniformly, we help pharma leaders improve the
quality, bioavailability, stability and process efficiency of their drugs.
Pharmaceutical
Microfluidizer processors enable researchers to
accomplish the previously impossible, such as the development of
innovative methods for targeted drug delivery using multi-functional
nanomedicine.
-
Vaccines/adjuvants
-
Cancer therapeutics
-
Antibiotics
-
Injectables
-
Inhalables
-
Liposomes
-
Anesthetics
-
Steroids
-
Drug nanosuspensions
-
High shear particle size reduction
-
Uniform particle size distribution
-
Guaranteed scaleup
-
Biopharma-grade models available
-
Continuous crystallization
-
Steam-in-Place capabilities
-
cGMP/21 CFR Part 11 compliance
-
50% smaller particles than conventional homogenizers
-
Improved bioavailability
-
Enhanced stability for extended shelf life
-
Targeted drug delivery
-
Sterile filtration (< 200 nm)
-
Less filter material required
-
Minimized or eliminated contamination
Tab three content - Lorem ipsum dolor sit amet,
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
exercitation ullamco laboris nisi ut aliquip ex ea commodo
consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do
eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
aliquip ex ea commodo consequat.